The pharmaceutical company Ferring has purchased rights to a phase-3 cancer treatment, which Ferring's Danish department will be working with in Europe. However, the acquisition does not mean that Ferring will become a cancer-focused firm, says Ferring's CEO in Denmark.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.